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The ataxia telangiectasia mutated (ATM) kinase 
is involved in transducing signals that are im-
plicated in the regulation of cell cycle check-
points, apoptosis, and DNA repair (1). The 
ATM-dependent pathway is activated early in 
the course of human tumorigenesis and serves 
as an anticancer barrier that helps to delay or 
prevent cancer (2). In turn, a defi  ciency  of 
ATM results in early onset of lymphomas in 
mice (3), whereas germline mutations in the 
ATM gene cause ataxia-telangiectasia, a multi-
system disorder that is associated with a pre-
disposition to lymphoma and acute leukemia (4). 
Regulation of the ATM-dependent pathway 
is complex and involves numerous positive 
and negative regulators (1). Among the latter, 
emerging data support a role for ATM phos-
phatases PP2A and Wip1 in controlling the 
magnitude and duration of ATM phosphoryla-
tion and activity after stress (5, 6).
There is increasing evidence that Wip1 
phosphatase can function as an oncogene (7, 8). 
The Wip1 gene, PPM1D, is amplifi  ed in  15% 
of primary human breast cancers, which leads 
to Wip1 overexpression. Transformation ex-
periments with rodent fi  broblasts have shown 
that the introduction of Wip1 along with Ras, 
Myc, or ErbB2 results in enhanced colony for-
mation in soft agar (7, 8). A combination of 
genetic and molecular studies have established 
that the oncogenic properties of Wip1 may re-
sult from its suppression of p53 functions (7, 8). 
Along this line, almost all Wip1-overexpressing 
breast tumors were found to have a structurally 
intact p53 gene, confi  rming that Wip1 could 
functionally inactivate p53 (7).
Regulation of several signaling pathways 
has been proposed by Wip1 phosphatase. 
  Modulation of the p38 MAPK signaling cascade 
was shown both in vitro and in vivo (9, 10). 
We found that activation of p38 MAPK could be 
critical in rendering Wip1-defi  cient mice resis-
tant to mammary gland tumors driven by ErbB2 
and Ras oncogenes (10). Further studies, how-
ever, revealed that in addition to p38 MAPK 
(11), Wip1 could effi   ciently dephosphorylate 
in vitro the serine residues on p53, H2AX, and 
Chk2 (6, 12, 13). Likewise, Wip1 phosphatase 
plays an important role in dephosphorylating 
ATM both in vitro and in vivo (6).
RESULTS AND DISCUSSION
Activation of the ATM-dependent tumor 
suppressor network could be critical in the 
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previously identifi  ed resistance of Wip1-defi  cient mice to 
tumorigenesis (6, 10). Wip1 phosphatase dephosphorylates 
ATM at Ser1981 and is required to reset ATM phosphory-
lation after DNA damage (6). ATM autophosphorylation as 
well as its binding with the Mre11/Rad50/NBS1 complex 
are the two major means of ATM activation after DNA 
damage (1). In turn, ATM autophosphorylation (apparently 
at several phospho sites; references 14 and 15) is suffi   cient to 
fully activate ATM (14). As Wip1 defi  ciency resulted in up-
regulation of ATM activity (6), which could not be fully 
explained by changes in Ser1981 phosphorylation (5,16), 
we asked whether Wip1 could dephosphorylate other auto-
phosphorylation sites on ATM. Using an in vitro phospha-
tase assay, we found that Ser367, but not Ser1893, was 
effi   ciently dephosphorylated by Wip1 in vitro (Table I). We 
further showed that Wip1 directly binds ATM’s N termi-
nus (amino acids 1–989) and FAT domain (amino acids 
1916–2644; Fig. 1 A), which contain Ser367 and Ser1981, 
respectively. These data further support a direct role of 
Wip1 in regulating ATM through dephosphorylation of 
multiple residues.
To further validate the signifi  cance of our fi  ndings on the 
role of Wip1 in regulation of ATM signaling, we identifi  ed 
Wip1-defi  cient splenocytes as a cell type with a high level of 
ATM phosphorylation at Ser1987 (human Ser1981). As the 
spleen is primarily comprised of B cells, we crossed Wip1-
defi  cient mice with Eμ-myc transgenic mice in which the 
expression of myc is restricted to B lymphocytes (17) to pro-
vide a physiologically relevant model for understanding the 
signifi  cance of ATM activation in suppressing tumorigenesis 
in Wip1-defi   cient mice. Analysis of splenocytes obtained 
from Wip1+/+ and Wip1−/− mice expressing Eμ-myc re-
vealed increased phosphorylation of ATM, p53 at the ATM 
target site Ser18 (human Ser15; Wip1+/+ Eμ-myc spleno-
cytes showed either no [Fig. 1 B, lane 1] or slight [Fig. 1 B, 
lane 2] p53 phosphorylation), as well as increased phosphory-
lation of p38 and its target, HSP-27 (Fig. 1 B and Fig. S1, 
which is available at http://www.jem.org/cgi/content/full/
jem.20061563/DC1). No diff  erence in the phosphorylation 
of Chk1 Ser345 was observed in splenocytes obtained from 
Wip1+/+ or Wip1−/− mice (Fig. 1 B).
To investigate tumor onset, we used only littermates from 
the same parents for all of our crosses. Next, we investigated 
whether ablation of Wip1 protects mice from Eμ-myc–
  induced B lymphomas. We crossed Wip1-null mice with Eμ-
myc transgenic mice and found that Wip1+/− and Wip1−/− 
mice were considerably more resistant to tumor formation 
induced by myc than wild-type mice (Fig. 1 C). The median 
Figure 1.  Wip1 defi  ciency suppressed myc-induced lymphomagenesis. 
(A) In vitro association of ATM fragments with Wip1. Bacteria-
expressed purifi  ed His-Wip1 was incubated with purifi  ed glutathione 
S-transferase (GST) or different GST-ATM fragments. Wip1 bound to ATM 
was detected after pull-down with glutathione-sepharose. The appropri-
ate GST fragments are marked with asterisks. (B) Levels of phosphoryla-
tion and the expression of different proteins were analyzed in splenocytes 
from two separate Wip1+/+ Eμ-myc and Wip1−/− Eμ-myc mice. (C) The 
occurrence of lymphomas in Wip1+/+, Wip1+/−, and Wip1−/− mice bear-
ing the Eμ-myc transgene was analyzed over 400 d. The MLS for different 
genotypes is shown at the top. (D) The levels of expression of different 
proteins were analyzed in tumor samples obtained from Wip1+/+ Eμ-myc 
(1–6) or Wip1−/− Eμ-myc (7–12) mice. (E) The level of ATM was analyzed 
in cultured lymphoma cells with or without caspase inhibitor zVAD-fmk.JEM VOL. 203, December 25, 2006  2795
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lifespan (MLS) in our cohort of Wip1+/+ mice was around 
77 d. In contrast, the MLS for Wip1+/− mice was 107 d (P = 
0.002) and for Wip1−/− mice was 138 d (P < 0.001).
The appearance of tumors in the Eμ-myc mouse B lym-
phoma model is due primarily to the high selective pressure 
placed on the ARF-p53 signaling cascade (18, 19). To under-
stand the spectrum of molecular changes in our set of tumors, 
we next analyzed extracts for the expression of diff  erent 
  proteins. We found that the level of p19Arf was increased in 6 
of the 12 analyzed tumors (Fig. 1 D). These tumors also showed 
either loss (samples 2, 8, and 11) or mutation (samples 5 and 
12), confi  rmed by the sequencing of the cDNAs of p53. We 
also observed the overexpression of Mdm2 protein in multi-
ple samples (Fig. 1 D). Our data are in agreement with a pre-
vious observation showing that high p19Arf levels result 
from absence of the p53-induced negative feedback loop due 
to overexpression of Mdm2 or inactivation of p53 (20). 
Interestingly, analysis of ATM levels revealed a reduction of 
ATM expression or its loss in multiple wild-type and Wip1-
null tumors (15 out of 34 analyzed tumors; Fig. 1 D and not 
depicted). Importantly, we found that tumors with reduced 
levels of ATM showed a strong correlation with normal lev-
els of p19Arf and structurally intact p53, supporting the idea 
that loss of ATM relieves pressure for the inactivation of p53 
downstream of myc (Fig. 1 D).
To gain insight into potential mechanisms of ATM loss in 
Eμ-myc tumors, we checked ATM mRNA by real-time 
PCR and for the presence of mutations by genomic sequencing. 
We found no diff  erence in the levels of ATM mRNA 
  between tumor samples that did or did not express ATM; 
likewise, no mutations in the ATM sequence were found 
(not depicted). Previous data suggest that ATM can undergo 
a caspase-dependent degradation upon induction of apoptosis 
(21, 22). To check this possibility, we treated the cultured 
lymphoma cells containing reduced levels of ATM with 10 μM 
of the caspase inhibitor zVAD-fmk (overnight incubation). 
As shown in Fig. 1 E, inactivation of caspases resulted in a 
dramatic increase in ATM levels.
We previously reported that activation of p38 MAPK was 
important in suppressing the early development of mammary 
gland tumors in Wip1-null mice (10). As it is critical to 
  understand any contribution of increased p38 MAPK signal-
ing to the resistance of Wip1-null mice for Eμ-myc–induced 
B cell lymphomas, we crossed Wip1-null mice with p38α 
knock-in mice. In these mice, the p38α regulatory sites 
Thr180 and Tyr182 are replaced by alanine and phenylala-
nine, respectively, thus disabling p38α activation by any 
stimuli (unpublished data). Next, we asked whether the pres-
ence of one mutant allele for p38α, which has dominant-
negative features, would be suffi     cient to attenuate p38 
activation in Wip1-defi  cient cells. Defi  ciency of Wip1 caused 
an increase in the phosphorylation of HSP27, a downstream 
target in the p38 MAPK cascade, in unirradiated cells, and 
mutation of one allele of p38α was suffi   cient to reduce HSP27 
phosphorylation to levels below those found in wild-type 
dermal fi  broblasts (Fig. 2 A, middle, lanes 1, 5, and 9, and 
Fig. S1). However, despite the fact that p38 MAPK was 
up-regulated in Wip1-defi  cient splenocytes expressing Eμ-
myc (Fig. 1 B), lowering the level of p38 activation (as in 
the p38αKI/+ mice) had no apparent eff  ect on the onset of 
B cell lymphomas (Fig. 2 B) because Wip1−/−p38αKI/+ 
Eμ-myc mice remained tumor resistant (MLS = 131 d for 
Figure 2.  p38 MAPK is not required to render Wip1-defi  cient 
mice resistant to Myc-induced lymphomas. (A) The levels of phospho-
rylation of p38 and its target HSP27 were analyzed in dermal fi  broblasts 
purifi  ed from wild-type, Wip1−/−, or Wip1−/− p38αKi/+ mice. Cells were 
treated with different doses of ultraviolet C and harvested 1 h later. 
(B) The occurrence of lymphomas in Wip1+/+ p38αKi/+ or Wip1−/− p38αKi/+ 
mice bearing the Eμ-myc transgene was analyzed, and the MLS for the 
different genotypes is shown at the top.
Table I.  Kinetic parameters for the dephosphorylation of phosphopeptides by rWip1 at pH 7.5, 30°C
Substrate Sequence Km (μM) kcat (s–1) kcat/Km (103 × M–1 s–1)
ATM(1981pS) AFEEGpSQSTTI 31 ± 2 2.9 ± 0.1 94
ATM(367pS) RSLEIpSQSYTT 38 ± 2 1.5 ± 0.03 39
ATM(1893pS) NLDSEpSEHFFR >200 NDa NDa
p38(180pT 182pY) TDDEMpTGpYVAT 31 ± 3 2.0 ± 0.1 64
Values represent averages from three to four independent experiments.
aThe Km and kcat values could not be determined due to the high Km.2796  ATM/WIP1-DEPENDENT SUPPRESSION OF LYMPHOMAGENESIS | Shreeram et al.
Wip1−/−p38αKI/+ Eμ-myc vs. 85 d for p38αKI/+ Eμ-myc 
mice; P = 0.038).
Development of lymphomas in the Eμ-myc model is de-
pendent on the suppression of Arf/p53 signaling, as deletion 
of only one copy of either gene is suffi   cient to dramatically 
accelerate tumor onset (18, 19). In turn, Wip1-defi  cient cells 
possess a high level of p53 activity (10) and phosphorylation 
at Ser18 (Fig. 1 B). To understand whether inactivation of 
Trp53 or p19Arf is suffi   cient to eliminate the diff  erence be-
tween Wip1+/+ Eμ-myc and Wip1−/− Eμ-myc mice, we 
crossed Wip1+/− Eμ-myc mice with either Wip1+/−p53+/− 
or Wip1+/−Arf+/− mice. No diff  erence in tumor appearance 
between Wip1+/+p53+/− Eμ-myc and Wip1−/−p53+/− Eμ-
myc mice was found (P = 0.43); both groups of mice rapidly 
succumbed to tumors within 45 d of birth (Fig. 3 A). Analysis 
of the p53 status revealed loss of the second p53 allele in 
  tumors that developed in 60% (6 out of 10) of Wip1+/+ Eμ-
myc and 50% (6 out of 12) of Wip1−/− Eμ-myc mice. In 
contrast, although all Wip1+/+Arf+/− Eμ-myc mice rapidly 
developed tumors (Fig. 3 B) with a time of onset that was not 
signifi  cantly diff  erent from those in Wip1+/+p53+/− Eμ-myc 
mice (Fig. 3 A), Wip1−/−Arf+/− Eμ-myc mice remained 
  tumor resistant (P < 0.001).
Next, we intercrossed Arf+/−Wip1−/− Eμ-myc mice to 
check whether the loss of both copies of Arf would accelerate 
the onset of lymphomas in a Wip1-defi  cient background. 
We found that, in the absence of both copies of Arf, Wip1-
defi  cient mice remained tumor resistant. In a group of 10 
mice, all survived beyond 80 d without any sign of tumors.
As the ATM kinase appeared to be activated in Wip1-
null splenocytes, resulting in increased p53 phosphorylation 
at Ser18 (Fig. 1 B), we next checked the contribution of 
ATM in suppressing tumorigenesis induced by myc. Analysis 
of lymphoma formation revealed that heterozygocity of 
ATM did not accelerate tumorigenesis in either Wip1+/+ 
Eμ-myc or Wip1−/−ATM+/− Eμ-myc mice. Analysis of 
  tumors that arose in the ATM+/− Eμ-myc mice showed that 
none of 12 tumors lost the second ATM allele. Next, we ana-
lyzed tumor onset in an ATM-null background. As ATM-
null mice are prone to development of T cell, but not B cell, 
lymphomas (3), all tumors in the ATM−/− Eμ-myc back-
ground were analyzed and found to be B cell–derived lym-
phomas (B220+ CD4−; not depicted). Importantly, tumor 
onset for Wip1−/−ATM−/− Eμ-myc mice (Fig. 3 C) was 
signifi  cantly accelerated compared with Wip1−/− Eμ-myc 
mice (69 vs. 138 d [Fig. 1 C]; P < 0.001); thus, suppression 
of Eμ-myc–induced lymphomagenesis in Wip1-defi  cient 
mice is dependent on p53 (Fig. 3 A) and ATM (Fig. 3 C).
As tumor development in Eμ-myc lymphomas is due pri-
marily to changes in rates of cell proliferation or apoptosis, 
we next checked the proliferation and apoptotic rates of 
  tumors arising in diff  erent genetic backgrounds. Although no 
diff  erence in the rates of proliferation was found between 
  diff  erent genotypes (Fig. 4 A), the level of TUNEL+ cells 
(an apoptosis marker) was reduced in mice with an ATM−/− 
background to the levels observed for either p53+/− or 
Arf+/− tumors (Fig. 4 B). Interestingly, loss of one copy of 
Arf almost completely eliminated apoptosis in Wip1+/+/
Arf+/− Eμ-myc tumors, whereas Wip1−/−/Arf+/− Eμ-myc 
tumors retained levels of apoptosis comparable to those of 
wild-type/Eμ-myc tumors.
We next investigated whether the p19Arf–Mdm2–p53 
pathway had been inactivated in the Eμ-myc tumors arising 
in ATM mutant mice, as inactivation is common in wild-
type and Wip1-defi  cient backgrounds (Fig. 1 D). The level 
of p19Arf is a sensitive indicator for the functionality of this 
pathway (20). Although  40% of tumors arising in wild-type 
and Wip1-defi  cient mice overexpressed Arf (Fig. 1 D), which 
is similar to the incidence reported by others (18–20), none 
of the tumors from Wip1+/+/ATM−/− mice (0 of 12, with 
Figure 3.  Wip1 defi  ciency suppressed myc-induced lymphoma-
genesis in an ATM/p53-dependent, Arf-independent manner. 
(A) The occurrence of lymphomas in Wip1+/+ p53+/− or Wip1−/− p53+/− 
mice bearing the Eμ-myc transgene was analyzed, and the MLS for different 
genotypes is shown at the top. (B) The occurrence of lymphomas in 
Wip1+/+ Arf+/− and Wip1−/− Arf+/− mice bearing the Eμ-myc transgene 
was analyzed, and the MLS for different genotypes is shown at the top. 
(C) The occurrence of lymphomas in Wip1+/+ ATM−/− and Wip1−/− 
ATM−/− mice bearing the Eμ-myc transgene was analyzed, and the MLS 
for different genotypes is shown at the top. JEM VOL. 203, December 25, 2006  2797
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4 shown in Fig. 4 C, lanes 1–4) did so. Moreover, none of 
the tumors from Wip1+/+/ATM−/− mice showed loss or 
mutation of p53 (0 of 12, with 4 shown in Fig. 4 C, 
lanes 1–4).
Removal of ATM accelerated tumor onset in Wip1-
  defi  ceint mice (Fig. 3 C); however, analysis of the p19Arf–p53 
pathway revealed its deregulation in 2 of the 12 analyzed tu-
mors that developed in Wip1/ATM double-defi  cient mice 
expressing Eμ-myc (1 shown in Fig. 4 C, lane 5). Both tu-
mors showed a high level of p53 and p19Arf, and subsequent 
sequencing revealed mutations in the p53 cDNAs (gaa [Glu] 
to aaa [Lys] at codon 283, and gcc [Ala] to gac [Asp] at codon 
158). Thus, besides ATM, Wip1-defi  cient cells may use 
  additional pathway(s) to activate p53.
Recent data suggest that Wip1 directly dephosphorylates 
Ser15 of human p53 (12). As p53 Ser15 is a direct target for 
the ATM kinase, which, in turn, is activated in Wip1-defi  cient 
cells, we next asked whether removal of ATM would be 
suffi     cient to reduce the level of p53 phosphorylation at 
Ser18 (human Ser15). Analysis of p53 Ser18 phosphoryla-
tion, as shown in Fig. 4 D, revealed that deletion of ATM 
completely eliminated the diff  erence between wild-type and 
Wip1-null splenocytes. Thus, although additional mecha-
nisms besides ATM may contribute to p53 activation in 
Wip1-defi  cient B cells, they are independent of p53 phos-
phorylation at Ser15 and Chk1 at Ser345 (Figs. 1 B and 4 D).
Here, we show that defi  ciency of Wip1 phosphatase con-
tributes to suppression of myc-induced lymphomagenesis in 
an ATM/p53-dependent manner. In turn, the role of ATM 
in suppressing the early onset of lymphomas is critical, as 
  deletion of ATM from Eμ-myc mice dramatically acceler-
ated tumorigenesis (MLS = 77 d for ATM+/+ Eμ-myc vs. 
41 d for ATM−/− Eμ-myc mice), and some Eμ-myc tu-
mors showed a loss or a reduction in ATM expression. Loss 
of ATM resulted in a dramatic decrease in the rate of apop-
tosis and removed the strong selective pressure for func-
tional inactivation of the p53 apoptotic pathway during 
myc-induced lymphomagenesis (Fig. 4, B and C). Importantly, 
ATM could be critical during physiological class switching 
for preventing myc-induced tumorigenesis by inhibiting 
translocations between c-myc and the IgH locus in primary 
B cells (23).
Myc is a potent inducer of apoptosis, and reduction or 
loss of ATM protein in Eμ-myc–induced lymphomas ap-
peared to be through its caspase-dependent degradation (Fig. 
1 E). As the presence of ATM is critical in executing the p53 
apoptotic pathway during myc-induced lymphomagenesis 
(Fig. 4 B), it is possible that in the course of tumorigenesis a 
substantial number of B cells have reduced ATM levels due 
to myc-dependent activation of caspases. In turn, when the 
level of ATM falls below the threshold required to maintain 
activation of the p53 apoptotic pathway, development of 
lymphomas occurs. However, even in those cases when the 
level of ATM is lowered to reduce apoptosis and cause lym-
phoma development in wild-type mice, defi  ciency in Wip1 
phosphatase will activate the remaining pool of ATM (Fig. 4 E; 
reference 6). This activation, in turn, signals to p53, which 
initiates apoptosis at a level suffi   cient to protect B cells from 
myc-induced lymphomagenesis, even when both copies of 
p19Arf have been lost.
Figure 4.  ATM is critical in the activation of myc-induced 
apoptosis. (A) The mitotic index based on analysis of phospho-histone H3+ 
cells was determined in tumors that arose in different backgrounds. 
(B) Apoptosis based on analysis of TUNEL+ cells was measured in tumors 
that arose in different backgrounds. (C) The levels of p53, p19Arf, and p38 
(loading control) were analyzed in ATM−/− Eμ-myc tumors with wild-type 
(1–4) or Wip1−/− (5–8) backgrounds. (D) The levels of p53 and p53 phos-
phorylation at Ser18 were analyzed in wild-type, Wip1, and Wip1/ATM 
double-defi  cient splenocytes expressing Eμ-myc. (E) A diagram illustrating 
the role of the Wip1 phosphatase in suppressing lymphomagenesis in the 
presence of myc.2798  ATM/WIP1-DEPENDENT SUPPRESSION OF LYMPHOMAGENESIS | Shreeram et al.
It was well established that protection from tumorigenesis 
in the Eμ-myc model of B lymphomas is dependent on the 
presence of p53 and Arf, as deletion of only one copy of 
  either gene is suffi   cient to dramatically accelerate tumor on-
set (18, 19). In turn, a recent analysis of the eff  ects of Arf 
  revealed that its overexpression is suffi   cient  to  increase 
ATM-dependent signaling to p53, probably through a 
Tip60-dependent acetylation of ATM (24, 25). In a similar 
scenario, overexpression of E2F1, another effi   cient inducer 
of Arf expression, was shown to result in the phosphorylation 
of p53 at serine 15 via ATM (26). Thus, activation of p53 in 
the presence of myc can be achieved through both the ATM 
signaling network as well as through Arf-mediated inhibition 
of Mdm2-dependent repression and degradation of p53 (Fig. 
4 E). On the other hand, overexpression of Wip1, as occurs 
in certain types of cancers (7, 8), may accelerate tumorigene-
sis by inhibiting ATM. In turn, inactivation of the Wip1 
phosphatase with subsequent activation of ATM/p53 signal-
ing could be critical for suppressing tumorigenesis in B cells 
and likely other tumor types.
MATERIALS AND METHODS
Mouse strains. All animal protocols used in this study were approved 
by the Institute of Molecular and Cell Biology Animal Safety and Use 
Committee. We crossed Wip1+/− mice with p53+/−, p19Arf+/−, ATM+/−, 
p38αKI/+ (unpublished data), or FVB/N Eμ-myc mice to obtain mice of 
diff   erent genotypes. p19Arf heterozygous and ATM heterozygous mice 
were obtained from the NCI Mouse Repository and The Jackson Labora-
tory, respectively. FVB/N Eμ-myc mice were from Charles River Labo-
ratories (Wilmington, MA). Mice were checked for tumors twice a week 
by palpation.
Western blotting. We prepared cell lysates as described previously (10). 
Immunoblots were probed with antibodies to phospho-ATM (Ser 1981; 
Chemicon International), phospho-p53 (Ser15), phospho-p38 (Thr180/
Tyr182), phospho-HSP27 (Ser82), and total p38 (C-20; Santa Cruz 
Biotechnology, Inc.). Antibody to ATM (2C1) was from GeneTex and 
  antibody to p19Arf was from Abcam. As secondary antibodies, we used 
  peroxidase-conjugated IgGs (Jackson ImmunoResearch Laboratories), followed 
by enhanced chemiluminescence detection (GE Healthcare).
Real-Time PCR. Total RNA was extracted using Trizol reagent accord-
ing to the manufacturer’s protocol (Invitrogen). cDNA synthesis was per-
formed using a mixture of random and oligo(dT) primers and SuperScript II 
reverse transcriptase (Invitrogen). Real-time PCR analysis of the mouse 
ATM, Cdkn2a, and the reference mRNA for cyclophilin A was performed 
with the LightCycler Rapid Thermal Cycler System (Roche Diagnostics 
Ltd.). Reactions were performed in a 10-μl volume with 1 μM primers, 
nucleotides, and LightCycler-DNA Master SYBR Green I mix (Roche 
Diagnostics Ltd.). A typical protocol included a 10-min denaturation step 
followed by 40 cycles with a 95°C denaturation for 20 s, 59°C annealing 
for 20 s, and 72°C extension for 20 s. For quantitative analysis of the p19Arf 
genomic locus, we purifi  ed genomic DNA using the DNeasy Tissue kit 
(QIAGEN) and analyzed four diff  erent genomic fragments spanning 18 kb 
of the p19Arf genomic locus using the above protocol. The primer sequences 
are available upon request.
Online supplemental material. Fig. S1 shows quantitative analysis of the 
results in Figs. 1 B and 2A. It is available at http://www.jem.org/cgi/
content/full/jem.20061563/DC1.
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